SCHEMBL30206258

SCHEMBL30206258

CNc1nc(Nc2ccc(CN3C[C@@H]4C[C@H]3CO4)cc2F)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 2/20 0.37
▸ LRRK2 Q5S007 2/20 0.35
▸ CCNC P24863 2/20 0.34
▸ CDK8 P49336 2/20 0.34
▸ BRAF P15056 2/20 0.33
▸ FPR2 P25090 3/20 0.33
▸ WNT3A P56704 1/20 0.32
▸ ABCB11 O95342 1/20 0.31
▸ NQO2 P16083 1/20 0.31
▸ MAP2K2 P36507 1/20 0.31
▸ MAP2K1 Q02750 1/20 0.31
▸ METTL3 Q86U44 1/20 0.31
▸ WNT1 P04628 2/20 0.30
▸ GSK3B P49841 2/20 0.30
▸ DYRK1A Q13627 2/20 0.30
▸ JAK2 O60674 1/20 0.30
▸ JAK1 P23458 1/20 0.30
▸ IDH1 O75874 1/20 0.30
▸ MTOR P42345 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30205936 1.00 TLR7 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL24944781 1.00 TLR7 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL24944495 1.00 TLR7 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL24944493 1.00 TLR7 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL31577349 0.94 TLR7 (0.36) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL30206282 0.94 LRRK2 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL30206277 0.94 LRRK2 (0.37) TLR7LRRK2CCNCCDK8BRAF
SCHEMBL24944780 0.89 LRRK2 (0.34) TLR7LRRK2CCNCCDK8FPR2
SCHEMBL30205960 0.89 LRRK2 (0.34) TLR7LRRK2CCNCCDK8FPR2
SCHEMBL24944753 0.88 LRRK2 (0.37) LRRK2FPR2ABCB11NQO2MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 TLR7 4346/4885LRRK2 3283/4885CCNC 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback